Prenatal gene therapy for the early treatment of genetic disorders

LAUR Repository

Show simple item record

dc.contributor.author Abi Nader, Khalil
dc.contributor.author Rodeck, Charles H.
dc.contributor.author David, Anna L.
dc.date.accessioned 2016-06-08T11:13:19Z
dc.date.available 2016-06-08T11:13:19Z
dc.date.copyright 2009 en_US
dc.date.issued 2016-06-08
dc.identifier.issn 1747-4108 en_US
dc.identifier.uri http://hdl.handle.net/10725/3982
dc.description.abstract renatal gene therapy aims to deliver genes to cells and tissues early in prenatal life, allowing the correction of a genetic defect before long-term tissue damage has occurred. In contrast to postnatal gene therapy, prenatal application has a number of advantages, including targeting genes in a large population of dividing stem cells, and the smaller fetal size, which allows a higher vector-to-target cell ratio to be achieved. Early gestational delivery may result in the fetus developing immune tolerance to the transgenic protein, which would allow postnatal repeat of vector administration if needed. Recent advances in vector design and stem cell research have benefited this potential treatment. Although still in the preclinical stage, proof-of-principle studies in animal models of congenital disease, such as the hemophilic mouse, have shown the potential of prenatal gene therapy. Investigators have devised delivery strategies in large animals that could be used clinically to apply gene therapy to a human fetus, and prenatal gene therapy may be available for the treatment of certain life-threatening congenital disorders in the near future. With this treatment, pregnant women and their partners would have a third choice when faced with an affected fetus, where currently the only options are terminating the pregnancy or continuing with an affected fetus with a poor prognosis. A number of problems need to be resolved, including the long-term safety and efficacy of the therapy, the potential for germ-line gene transfer, how best to achieve informed consent for the therapy, as well as regulatory and ethical issues. In this article, we evaluate the current state and future implications of prenatal therapy in severe genetic diseases and outline the factors that will influence its movement into clinical practice. en_US
dc.language.iso en en_US
dc.title Prenatal gene therapy for the early treatment of genetic disorders en_US
dc.type Article en_US
dc.description.version Published en_US
dc.author.school SOM en_US
dc.author.idnumber 200902740 en_US
dc.author.department N/A en_US
dc.description.embargo N/A en_US
dc.relation.journal Expert Review of Obstetrics & Gynecology en_US
dc.journal.volume 4 en_US
dc.journal.issue 1 en_US
dc.article.pages 25-44 en_US
dc.keywords Fetus en_US
dc.keywords Gene therapy en_US
dc.keywords Genetic disorder en_US
dc.keywords Prenatal therapy en_US
dc.keywords Vector en_US
dc.identifier.doi http://dx.doi.org/10.1586/17474108.4.1.25 en_US
dc.identifier.ctation Abi-Nader, K. N., Rodeck, C. H., & David, A. L. (2009). Prenatal gene therapy for the early treatment of genetic disorders. Expert Review of Obstetrics & Gynecology, 4(1), 25-44. en_US
dc.author.email khalil.abinader@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url http://www.tandfonline.com/doi/abs/10.1586/17474108.4.1.25 en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account